{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T08:51:25Z","timestamp":1781686285603,"version":"3.54.5"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Supported by Charles University, Cooperatio Intensive Care Medicine Program, the Ministry of Health, Czech Republic\u2014conceptual development of research organization"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s43440-026-00836-8","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T09:15:30Z","timestamp":1772010930000},"page":"929-944","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Achieving target plasma concentrations of beta-lactam antibiotics in critically ill patients: a retrospective study of full-dose administration in the first 24\u00a0hours"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1448-0274","authenticated-orcid":false,"given":"Milada","family":"Hala\u010dov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0330-8479","authenticated-orcid":false,"given":"Marie","family":"Mieresov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2776-0793","authenticated-orcid":false,"given":"Jan","family":"Kubele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9903-5662","authenticated-orcid":false,"given":"Eva","family":"Klapkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8892-5996","authenticated-orcid":false,"given":"Dalibor","family":"\u010cern\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4668-5837","authenticated-orcid":false,"given":"Petr","family":"Waldauf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1559-4078","authenticated-orcid":false,"given":"Franti\u0161ek","family":"Du\u0161ka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"836_CR1","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1097\/01.CCM.0000098031.24329.10","volume":"31","author":"J Garnacho-Montero","year":"2003","unstructured":"Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med. 2003;31:2742\u201351.","journal-title":"Crit Care Med"},{"key":"836_CR2","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/jac5.1084","volume":"2","author":"DA Hammond","year":"2019","unstructured":"Hammond DA, McCreary EK, Rech MA, Smith MN, Yeo QM, Lusardi K, et al. Perceptions and practices for beta-lactam antibiotic dosing, administration, and monitoring in critically ill patients. J Am Coll Clin Pharm. 2019;2:468\u201376.","journal-title":"J Am Coll Clin Pharm"},{"key":"836_CR3","doi-asserted-by":"publisher","first-page":"102512","DOI":"10.1016\/j.xpro.2023.102512","volume":"4","author":"L Barnes","year":"2023","unstructured":"Barnes L, et al. Antimicrobial susceptibility testing to evaluate minimum inhibitory concentration values of clinically relevant antibiotics. STAR Protoc. 2023;4:102512.","journal-title":"STAR Protoc"},{"key":"836_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/cc9091","volume":"14","author":"FS Taccone","year":"2010","unstructured":"Taccone FS, Laterre PF, Dugernier T, Spapen H, Delattre I, Wittebole X, et al. Insufficient \u03b2-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care. 2010;14:1\u20139.","journal-title":"Crit Care"},{"key":"836_CR5","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1111\/aas.12808","volume":"60","author":"J Petersson","year":"2016","unstructured":"Petersson J, Giske CG, Eliasson E. Standard dosing of Piperacillin and meropenem fails to achieve adequate plasma concentrations in ICU patients. Acta Anaesthesiol Scand. 2016;60:1425\u201336.","journal-title":"Acta Anaesthesiol Scand"},{"key":"836_CR6","unstructured":"Adult Critical Care. http:\/\/www.gicu.sgul.ac.uk\/resources-for-current-staff\/supplementary-inpatient-prescription-charts\/renalbook.pdf\/view"},{"key":"836_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13054-019-2378-9","volume":"23","author":"R Guilhaumou","year":"2019","unstructured":"Guilhaumou R, Benaboud S, Bennis Y, Dahyot-Fizelier C, Dailly E, Gandia P, et al. Optimization of treatment with beta-lactam antibiotics in critically ill patients: guidelines from SFPT and SFAR. Crit Care. 2019;23:1\u201320.","journal-title":"Crit Care"},{"key":"836_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40560-020-00504-w","volume":"8","author":"C Scharf","year":"2020","unstructured":"Scharf C, Liebchen U, Paal M, Taubert M, Vogeser M, Irlbeck M, et al. The higher the better? Defining the optimal beta-lactam target for critically ill patients to reach infection resolution and improve outcome. J Intensive Care. 2020;8:1\u201310.","journal-title":"J Intensive Care"},{"key":"836_CR9","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.ijantimicag.2010.06.008","volume":"36","author":"JA Roberts","year":"2010","unstructured":"Roberts JA, Ulldemolins M, Roberts MS, McWhinney B, Ungerer J, Paterson DL, et al. Therapeutic drug monitoring of \u03b2-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents. 2010;36:332\u20139.","journal-title":"Int J Antimicrob Agents"},{"key":"836_CR10","unstructured":"European Medicines Agency. Cefepime: summary of product characteristics. 2023."},{"key":"836_CR11","unstructured":"European Medicines Agency. Meropenem: summary of product characteristics. 2023."},{"key":"836_CR12","unstructured":"European Medicines Agency. Piperacillin\/Tazobactam: summary of product characteristics. 2023."},{"key":"836_CR13","unstructured":"EUCAST website. Available from: http:\/\/www.eucast.org\/clinical_breakpoints"},{"key":"836_CR14","first-page":"1","volume":"2","author":"Kidney Disease: Improving Global Outcomes Acute Kidney Injury Work Group","year":"2012","unstructured":"Kidney Disease: Improving Global Outcomes Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1\u2013138.","journal-title":"Kidney Int Suppl"},{"key":"836_CR15","doi-asserted-by":"publisher","first-page":"870","DOI":"10.3390\/antibiotics12050870","volume":"12","author":"A Legg","year":"2023","unstructured":"Legg A, Carmichael S, Chai MG, Roberts JA, Cotta MO. Beta-lactam dose optimisation in the intensive care unit: targets, therapeutic drug monitoring and toxicity. Antibiotics. 2023;12:870.","journal-title":"Antibiotics"},{"key":"836_CR16","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40265-018-0880-z","volume":"78","author":"AE Muller","year":"2018","unstructured":"Muller AE, Huttner B, Huttner A. Therapeutic drug monitoring of beta-lactams and other antibiotics in the intensive care unit. Drugs. 2018;78:439\u201351.","journal-title":"Drugs"},{"key":"836_CR17","first-page":"e0446","volume":"3","author":"EF Barreto","year":"2021","unstructured":"Barreto EF, Webb AJ, Pais GM, Rule AD, Jannetto PJ, Scheetz MH. Setting the beta-lactam therapeutic range for critically ill patients. Crit Care Explor. 2021;3:e0446.","journal-title":"Crit Care Explor"},{"key":"836_CR18","first-page":"87","volume":"39","author":"C Boidin","year":"2020","unstructured":"Boidin C, Moshiri P, Dahyot-Fizelier C, Goutelle S, Lefeuvre S. Pharmacokinetic variability of beta-lactams in critically ill patients. Anaesth Crit Care Pain Med. 2020;39:87\u2013109.","journal-title":"Anaesth Crit Care Pain Med"},{"key":"836_CR19","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1093\/jac\/dkx209","volume":"72","author":"S Imani","year":"2017","unstructured":"Imani S, Buscher H, Marriott D, Gentili S, Sandaradura I. \u03b2-lactam concentration\u2013toxicity relationships: a retrospective study. J Antimicrob Chemother. 2017;72:2891\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"836_CR20","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.cmi.2017.01.005","volume":"23","author":"T Huwyler","year":"2017","unstructured":"Huwyler T, Lenggenhager L, Abbas M, Lorenzini KI, Hughes S, Huttner B, et al. Cefepime plasma concentrations and clinical toxicity. Clin Microbiol Infect. 2017;23:454\u20139.","journal-title":"Clin Microbiol Infect"},{"key":"836_CR21","first-page":"497","volume":"81","author":"M Beumier","year":"2015","unstructured":"Beumier M, Casu GS, Hites M, Wolff F, Cotton F, Vincent JL, et al. Elevated \u03b2-lactam concentrations are associated with neurological deterioration in ICU septic patients. Minerva Anestesiol. 2015;81:497\u2013506.","journal-title":"Minerva Anestesiol"},{"key":"836_CR22","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s00134-015-3934-7","volume":"41","author":"EA Hoste","year":"2015","unstructured":"Hoste EA, Bagshaw SM, Bellomo R, Cely CM, Colman R, Cruz DN, et al. Epidemiology of acute kidney injury in critically ill patients: the AKI-EPI study. Intensive Care Med. 2015;41:1411\u201323.","journal-title":"Intensive Care Med"},{"key":"836_CR23","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13613-017-0260-y","volume":"7","author":"R Bellomo","year":"2017","unstructured":"Bellomo R, Ronco C, Mehta RL, Asfar P, Boisram\u00e9-Helms J, Darmon M, et al. Acute kidney injury in the ICU: from injury to recovery. Ann Intensive Care. 2017;7:49.","journal-title":"Ann Intensive Care"},{"key":"836_CR24","doi-asserted-by":"publisher","first-page":"ofae059","DOI":"10.1093\/ofid\/ofae059","volume":"11","author":"NF Aldardeer","year":"2024","unstructured":"Aldardeer NF, Alshreef MM, Alharbi EA, Aljabri AK, Aljawadi MH, Almangour TA, et al. Early versus late antipseudomonal \u03b2-lactam dose adjustment in sepsis with acute kidney injury. Open Forum Infect Dis. 2024;11:ofae059.","journal-title":"Open Forum Infect Dis"},{"key":"836_CR25","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1097\/01.ccm.0000811968.90871.ca","volume":"50","author":"B August","year":"2022","unstructured":"August B, Pauley N, Conrath M, Johnson J, Smith Z. Early antipseudomonal beta-lactam renal dose adjustment in sepsis and acute kidney injury. Crit Care Med. 2022;50:708.","journal-title":"Crit Care Med"},{"key":"836_CR26","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/phar.2842","volume":"43","author":"LT Hong","year":"2023","unstructured":"Hong LT, Downes KJ, FakhriRavari A, Abdul-Mutakabbir JC, Kuti JL, Jorgensen S, et al. International consensus recommendations for prolonged-infusion beta-lactams. Pharmacotherapy. 2023;43:740\u201377.","journal-title":"Pharmacotherapy"},{"key":"836_CR27","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/ki.2011.322","volume":"80","author":"GR Matzke","year":"2011","unstructured":"Matzke GR, Aronoff GR, Atkinson AJ Jr, Bennett WM, Decker BS, Eckardt KU, et al. Drug dosing considerations in patients with kidney disease: a clinical update from KDIGO. Kidney Int. 2011;80:1122\u201337.","journal-title":"Kidney Int"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00836-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-026-00836-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00836-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T07:52:08Z","timestamp":1781682728000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-026-00836-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["836"],"URL":"https:\/\/doi.org\/10.1007\/s43440-026-00836-8","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"7 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol was approved by the Na Homolce Hospital Research Ethics Board (approval number: 09_F_NNH_027; registration number: 11). We obtained consent from patients or their family members to publish anonymised and aggregated data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}